Syndax Pharmaceuticals (SNDX) Tops Q1 EPS by 14c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.48), $0.14 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $64.9 million versus the consensus estimate of $71.84 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• H.C. Wainwright Reiterates Buy Rating on Lifeward (LFWD)
• Envoy Medical (COCH) PT Lowered to $2 at H.C. Wainwright